Barclays’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-30,163
| Closed | -$647K | – | 5411 |
|
|
2026
Q1 | $647K | Sell |
30,163
-262,162
| -90% | -$3.69M | ﹤0.01% | 3032 |
|
|
2025
Q4 | $2.72M | Sell |
292,325
-54,860
| -16% | -$458K | ﹤0.01% | 2704 |
|
|
2025
Q3 | $2.45M | Sell |
347,185
-924
| -0.3% | -$6.36K | ﹤0.01% | 2739 |
|
|
2025
Q2 | $2.26M | Buy |
348,109
+192,900
| +124% | +$1.33M | ﹤0.01% | 2750 |
|
|
2025
Q1 | $1.23M | Buy |
155,209
+13,757
| +10% | +$148K | ﹤0.01% | 2975 |
|
|
2024
Q4 | $1.79M | Buy |
141,452
+6,079
| +4% | +$84.6K | ﹤0.01% | 2968 |
|
|
2024
Q3 | $1.89M | Buy |
135,373
+79,779
| +144% | +$1.14M | ﹤0.01% | 2900 |
|
|
2024
Q2 | $766K | Sell |
55,594
-11,872
| -18% | -$174K | ﹤0.01% | 2762 |
|
|
2024
Q1 | $1.11M | Sell |
67,466
-118,373
| -64% | -$1.77M | ﹤0.01% | 3032 |
|
|
2023
Q4 | $2.71M | Buy |
185,839
+53,957
| +41% | +$654K | ﹤0.01% | 2660 |
|
|
2023
Q3 | $1.62M | Sell |
131,882
-12,521
| -9% | -$163K | ﹤0.01% | 2015 |
|
|
2023
Q2 | $1.72M | Buy |
144,403
+70,834
| +96% | +$925K | ﹤0.01% | 1973 |
|
|
2023
Q1 | $984K | Sell |
73,569
-35,983
| -33% | -$703K | ﹤0.01% | 2744 |
|
|
2022
Q4 | $2.36M | Buy |
109,552
+19,123
| +21% | +$392K | ﹤0.01% | 2153 |
|
|
2022
Q3 | $1.81M | Buy |
90,429
+89,257
| +7,616% | +$1.9M | ﹤0.01% | 1821 |
|
|
2022
Q2 | $21K | Sell |
1,172
-4,315
| -79% | -$44.6K | ﹤0.01% | 4373 |
|
|
2022
Q1 | $55K | Buy |
+5,487
| New | +$72.5K | ﹤0.01% | 4079 |
|
Other funds holding DAWN
Barclays's DAWN Position: Q2 2026 in Review
Barclays sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 30,163 shares — an estimated $647K sold.
Barclays first reported a position in DAWN in Q1 2022 and held it in 17 quarters. The position peaked at $2.72M in Q4 2025. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Barclays reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Barclays sold 30,163 Day One Biopharmaceuticals shares in Q2 2026, an estimated $647K.
- Barclays first reported a position in Day One Biopharmaceuticals in Q1 2022 and held it in 17 quarters.
- Barclays's Day One Biopharmaceuticals position peaked at $2.72M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.